|
|
Volumn 3, Issue 1, 2001, Pages 19-26
|
|
Overcoming drug resistance in ovarian carcinoma.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
CISPLATIN;
PACLITAXEL;
CANCER STAGING;
COMPARATIVE STUDY;
DOSE RESPONSE;
DRUG RESISTANCE;
FEMALE;
HUMAN;
MAXIMUM TOLERATED DOSE;
MORTALITY;
NEOPLASM;
OVARY TUMOR;
PATHOLOGY;
PHASE 3 CLINICAL TRIAL;
PROGNOSIS;
REVIEW;
RISK ASSESSMENT;
SURVIVAL;
TREATMENT OUTCOME;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
CISPLATIN;
CLINICAL TRIALS, PHASE III;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG RESISTANCE, NEOPLASM;
FEMALE;
HUMANS;
MAXIMUM TOLERATED DOSE;
NEOPLASM STAGING;
NEOPLASMS, GLANDULAR AND EPITHELIAL;
OVARIAN NEOPLASMS;
PACLITAXEL;
PROGNOSIS;
RISK ASSESSMENT;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 0002871489
PISSN: 15233790
EISSN: None
Source Type: Journal
DOI: 10.1007/s11912-001-0038-z Document Type: Review |
|
Times cited : (16)
|
|
References (65)
|
